Alzheon company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series D | Alive

Total Raised


Last Raised

$50M | 2 yrs ago

About Alzheon

Alzheon is an American clinical-stage biopharmaceutical. The company develops medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Alzheon was founded in 2013 and is based in Farmingham, Massachusetts.

Alzheon Headquarter Location

111 Speen Street Suite 306

Framingham, Massachusetts, 01701,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alzheon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alzheon is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,128 items


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alzheon Patents

Alzheon has filed 10 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Alzheimer's disease
  • Cognitive disorders
patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Neurological disorders, Alzheimer's disease, Psychiatric diagnosis, Rare diseases


Application Date


Grant Date



Related Topics

Prodrugs, Neurological disorders, Alzheimer's disease, Psychiatric diagnosis, Rare diseases



Latest Alzheon News

Years after failed IPO attempts, Alzheon raises $50M round for Alzheimer’s study

Apr 16, 2022

APR 15, 2022 | 2:04 PM PDT | BIOCENTURY | FINANCEYEARS AFTER FAILED IPO ATTEMPTS, ALZHEON RAISES $50M ROUND FOR ALZHEIMER’S STUDYBY With Phase III Alzheimer’s trial finally in progress, Alzheon’s new $50M series D arrives four years after first attempt to go public© 2022 BioCentury Inc. All Rights Reserved

Alzheon Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alzheon Rank

  • When was Alzheon founded?

    Alzheon was founded in 2013.

  • Where is Alzheon's headquarters?

    Alzheon's headquarters is located at 111 Speen Street, Framingham.

  • What is Alzheon's latest funding round?

    Alzheon's latest funding round is Series D.

  • How much did Alzheon raise?

    Alzheon raised a total of $141.97M.

  • Who are the investors of Alzheon?

    Investors of Alzheon include National Institute on Aging, Paycheck Protection Program, Ally Bridge Group and ARCH Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.